Patents
Literature
8 results about "Isotype" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In immunology, the immunoglobulin (Ig) isotype (class) is encoded by the constant region segments of the immunoglobulin gene which form the Fc (Fragment crystallizable region) portion and the lower segment of the Fab (Fragment antigen-binding) portion of an antibody. The expression of a specific isotype determines the function of an antibody via the specific binding to Fc receptor molecules on different immune effector cells. Isotype expression reflects the maturation stage of a B cell. Naive B cells express IgM and IgD isotypes with unmutated variable genes, which are produced from the same initial transcript following alternative splicing. Expression of other antibody isotypes (IgD, IgM IgG1-4, IgA1-2, IgE) occurs via a process of class-switch recombination (CSR) after antigen exposure. Class-switching is mediated by the AID (activation-induced cytidine deaminase) enzyme and only occurs after the B cell binds an antigen through its B cell receptor, and is further activated through interaction with a T helper cell.
Hepatocyte nuclear factor four alpha antisense RNA 1 targeting polynucleotide and method of use and treatment thereof
The present invention comprises a pharmaceutic composition comprising one or more hepatocyte nuclear factor four alpha antisense RNA 1 (HNF4A-AS1) targeting polynucleotides, wherein the one or more HNF4A-AS1 targeting polynucleotides is capable of repressing HNF4A-AS1 in a subject resulting in upregulation of HNF4A expression and / or increasing HNF4A P1:P2 isoform ratio in the subject. The present invention also provides a method of treatment of a HNF4A-associated disease in a subject comprising the step of administering a therapeutically effective amount of the pharmaceutical composition comprising one or more HNF4A- AS1 targeting polynucleotides of the present invention. The present invention also provides a method of downregulating HNF4A P2 isoform expression in a subject comprising the step of repressing HNF4A-AS1 in the subject.
Owner:GENECO PTY LTD
MASP isotypes as inhibitors of complement activation
This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.
Owner:OMEROS CORP
Sirna for silencing a new isoform of the mitochondrial chaperone trap1
A siRNA characterised by having a sequence selected from the group comprised of: - SEQ ID NO. 1 : 5 ' CUCUUUCCCUUGAAUAAGC 3 '; - SEQ ID NO. 2 : 5 ' UGAUUCCCAAAGCUCACAG 3 '; and - a sequence including at least 16 contiguous nucleotides differing by no more than 3 nucleotides from SEQ ID No. 1 or SEQ ID No. 2, to silence TRAPl-low SEQ ID N°3. The use of the 5 'UTR SEQ ID N°4 region of the TRAPl-low transcript SEQ ID N°3 or a portion of that 5 'UTR region selected from the group comprised of: - the SEQ ID No. 6 portion of said 5 ' UTR region comprising nucleotide positions 1 through 644; - a portion of said region 5 ' UTR comprising the portion of SEQ ID No. 6 extended by a predetermined number of nucleotide positions beyond nucleotide position 644 along said region 5 'UTR.
Owner:C R O B CENT DI RIFERIMENTO ONCOLOGICO DELLA BASILICATA INST DI RICOVERO E CURA A CARATTERE SCIO +1
Monoclonal mouse antibodies against human estrogen receptor, human progesterone receptor, human ki-67, and human p53
PCT designated stageWO2026104883A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenPR - Progesterone receptor
Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.
Owner:FARZAM MOHAMMAD
Methods for assessing cardiac mesothelial cell distribution based on immunofluorescence images
ActiveCN121280349BGet a comprehensive understanding of dyeing performanceImprove recognition accuracyImage analysisAcquiring/recognising microscopic objectsImmunofluorescenceImaging analysis
This invention relates to the field of image analysis technology, specifically to a method for assessing the distribution of cardiac mesothelial cells based on immunofluorescence images. The method includes: acquiring multiple immunofluorescence images of cardiac mesothelial cells at different antibody concentrations within the assessment group; determining initial cardiac mesothelial cell regions based on the staining status of the isotype control group and the differences in staining depth among multiple staining regions in the immunofluorescence images; analyzing non-specific staining based on changes in the staining area and irregular cell boundaries of the initial cardiac mesothelial cell regions, and adjusting the antibody concentration accordingly; determining multiple target cardiac mesothelial cell regions, and obtaining the location information of the cardiac mesothelial cells based on the degree of overlap and similarity between these regions; and analyzing the spacing distribution of cardiac mesothelial cells and their distribution in the immunofluorescence images based on the location information to obtain the uniformity of the cardiac mesothelial cell distribution.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Anti-dr5 antibodies and methods of use thereof
PendingUS20260176368A1Hybrid immunoglobulinsPeptide/protein ingredientsAntiendomysial antibodiesCell Surface Antigens
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
Owner:GENMAB BV
Anti-CTLA-4 binding protein and its usage
PendingCN122080209AAntibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigen bindingDiagnostic methods
This document provides antigen-binding proteins (ABPs) that selectively bind to CTLA-4 and its isotypes and homologs, as well as compositions comprising said ABPs. Methods of using said ABPs, such as therapeutic and diagnostic methods, are also provided.
Owner:GIGAGEN INC
Anti-GPC1 monoclonal antibody, therapeutic and diagnostic uses thereof
PendingUS20260152569A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenAntiendomysial antibodies
A monoclonal antibody of IgM isotype which specifically binds to the antigen glypican-1 (GPC1) in vitro, ex vivo and in vivo, is able to induce complement dependent cytotoxicity and reduce GPC1-expressing tumor masses in vivo. A nucleic acid construct and a transformed host cell are suitable for use in a method of recombinantly producing the anti-GPC1 monoclonal antibody and in diagnostic and therapeutic methods.
Owner:CENT DI RIFERIMENTO ONCOLOGICO DI AVIANO +1